Yo Jyo Hen Shi Ko (YHK) Improves Transaminases in Nonalcoholic Steatohepatitis (NASH): A Randomized Pilot Study
NASH is a common condition with a rising incidence. There is progression to cirrhosis in some cases and the potential for mortality or requirement of liver transplantation. Currently, there is no approved therapy for NASH. The natural compound YHK has both anti-inflammatory and antifibrotic properties, and can lead to improvement in transaminases in viral hepatitis. Improvement in transaminases may correlate with improved histology in NASH and hence may impact on the natural history. We sought to determine the effects of YHK on NASH. We performed a randomized, double-blind, placebo-controlled pilot study to determine the effects of YHK on transaminases and on quality of life (QoL) in patients with biopsy-confirmed NASH and a persistently abnormal ALT or AST. Eight patients were randomized to YHK or placebo for 8 weeks. The ALT and AST were measured at baseline and weeks 4, 8, and 12. SF-36 surveys were serially completed. All five patients in the YHK group but none in the placebo group had a marked decrease in ALT at both week 4 and week 8 compared to baseline. After discontinuing YHK the ALT returned toward baseline at week 12. The mean decrease in ALT compared to baseline was significantly greater in the YHK group than in the placebo group at both week 4 (−42.8 ± 23.2 vs. −6.3 ± 6.7 U/L; P = 0.036) and week 8 (−45.4 ± 23.4 vs. 6.0 ± 24.6 U/L; P = 0.036). There was also a nonsignificant decrease in AST in the YHK group compared to placebo. QoL was not affected and no severe adverse events were reported. In this controlled pilot study we found the novel nutraceutical agent YHK to be effective at reducing ALT values in patients with NASH. YHK is well tolerated. Further studies are justified to assess the impact of YHK in the natural history of NASH.
Keywordsnonalcoholic steatohepatitis (NASH) Yo Jyo Hen Shi Ko (YHK) treatment
Unable to display preview. Download preview PDF.
- 5.Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK: Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99:1946–1952, 2004PubMedCrossRefGoogle Scholar
- 9.Marotta F, Harada M, Bertuccelli J, Rouge A, Anzulovic H, Yanaihara N, Ideo G: A nutritional approach with herbal remedy K-17,22 delays the onset of spontaneous chronic pancreatitis. J Pancreas 2(Suppl 5):350, 2001Google Scholar
- 11.Marotta F, Rouge A, Harada M, Anzulovic H, Ideo GM, Yahaihara N, Princess G, Ideo G: Beneficial effect of a controlled Chinese herbal remedy, K-17,22, in CCl4-induced liver toxicity: an in vivo and in vitro study. Biomed Res 22:167–174, 2001Google Scholar
- 12.Marotta F, Bertuccelli J, Albergati F, Harada M, Safran P, Yanaihara N, Ideo G: Ischemia-reperfusion liver injury : effect of a nutritional approach with K-17,22 on hepatic antioxidant defense system. Biomed Res 22:221–228, 2001Google Scholar
- 13.Harada M, Marotta F, Sha SH, Minelli E: YHK, a novel herbal remedy with effective antifibrotic action, in chronic liver disease: a pilot clinical study aiming to a successful integrative medicine development. First JSH Single Topic Conference, Yamanashi, Japan, November 14–15, 2002Google Scholar
- 14.Sha S, Harada M, Yanaihara N: Effect of YHK, a new Chinese herb prescription, on serum ALT and AST levels in patients with hepatic diseases. IASL-APASL Joint Meeting 2000, New Insights of Hepatology in the 21st Century, Fukuoka, Japan, June 2–7, 2000Google Scholar
- 23.Miyake K, Tango T, Ota Y, Mitamura K, Yoshiba M, Kako M, Hayashi S, Ikeda Y, Hayashida N, Iwabuchi S, Sato Y, Tomi T, Funaki N, Hashimoto N, Umeda T, Miyazaki J, Tanaka K, Endo Y, Suzuki H: Efficacy of Stronger Neo-Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis. J Gastroenterol Hepatol 17:1198–1204, 2002PubMedCrossRefGoogle Scholar